(1R,4r)-N1-(pyridin-2-yl)cyclohexane-1,4-diamine

Catalog No. :
ACTRLH953
CAS No. :
332883-96-2
Molecular Formula :
C11H17N3
Molecular Weight :
191.28

IUPAC Name:(1r,4r)-N1-(pyridin-2-yl)cyclohexane-1,4-diamine

(1R,4r)-N1-(pyridin-2-yl)cyclohexane-1,4-diamine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg97%$238.00Login to see priceInquiryInquiry
100mg97%$347.00Login to see priceInquiryInquiry
250mg97%$487.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(1R,4r)-N1-(pyridin-2-yl)cyclohexane-1,4-diamine
IUPAC Name(1r,4r)-N1-(pyridin-2-yl)cyclohexane-1,4-diamine
MDL No.MFCD22375210
Molecular FormulaC11H17N3
Molecular Weight191.28
SMILESN[C@H]1CC[C@H](NC2=NC=CC=C2)CC1
InChI KeyQQJKATBTUNOFBF-MGCOHNPYSA-N
Synonym(1R*,4R*)-1-N-(Pyridin-2-yl)cyclohexane--1,4-diamine;trans-N1-2-Pyridinyl-1,4-cyclohexanediamine;1-N-(pyridin-2-yl)cyclohexane-1,4-diamine, trans;1,4-Cyclohexanediamine, N1-2-pyridinyl-, trans-;trans-1-N-(Pyridin-2-yl)cyclohexane-1,4-diamine;1-N-(Pyridin-2-yl)cyclohexane-1,4-diamine
CAS No.332883-96-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACTRLH953 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTRLH953 route product structure diagram
    ACTRLH953332883-96-2
Inquiry

2. ACTRLH953 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACFHXR638 route compound structure diagram
    ACFHXR638109-04-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTRLH953 route product structure diagram
    ACTRLH953332883-96-2
Inquiry

Comments (0)